Tianjin Lisheng Pharmaceutical Company Ltd.

Tianjin Lisheng Pharmaceutical Co., Ltd. is a pharmaceutical manufacturing company established in 2001, following the restructuring of the Tianjin Lisheng Pharmaceutical Plant, which has a history dating back to 1951. The company was listed on the Shenzhen Stock Exchange in April 2010 and operates primarily in the manufacturing sector, focusing on both traditional Chinese medicine and Western medicine. Its product offerings include tablets, hard capsules, granules, drop pills, lyophilized powder for injection, water injection, and active pharmaceutical ingredients. The company has developed a comprehensive industrial chain, producing its own raw materials to ensure quality and reduce production costs. Tianjin Lisheng Pharmaceutical has established a strong market presence with a wide range of products, including 15 main categories and 243 approved products. It has formed strategic partnerships with major distributors such as China Resources and Sinopharm, enabling effective nationwide distribution. The company operates two wholly-owned subsidiaries and five joint-stock companies, and is recognized as a high-tech enterprise, benefiting from a preferential income tax rate.

1. Having a rather high reputation for its brand and quality and a high level of customer acceptance.The Company unremittingly improves its product quality and enhances its brand value. Through many years of efforts, Tianjin Lisheng Pharmaceutical Co., Ltd. has established its good product reputation and corporate image in the market, and its flagship product brand “Shoubishan” has long been well accepted by the public. The Shoubishan (“Indapamide Tablets”) is awarded again as “The Excellent Product Brand in the Chinese Chemical Pharmaceutical Industry 2017” at the ChemPharm Annual Summit 2017.2. Having a complete industrial chain with raw materials and preparations integrated.With a complete industrial chain, the Company itself produces all the raw materials needed for its main preparations. Thus the quality of the preparations is guaranteed from the source, and production costs and pollutant emissions are effectively reduced through an increased yield.3. Excellent commercial channels.The Company has already forged strategic partnerships with China Resources, Sinopharm, and Jointown Pharmaceutical Group Limited. Its distribution channels spread across the country, and the development of its clinical products has begun to take shape as well.4. A wide diversity of products.The Company and its wholly-owned subsidiaries have 15 main categories and 243 approval numbers of products.5. The advantage as a listed company.As a listed company, the Company has alternative financing sources or channels, ample funds, and strong anti-risk capabilities.